Literature DB >> 8250086

Nadolol in the treatment of central serous retinopathy.

D J Browning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8250086     DOI： 10.1016/s0002-9394(14)73483-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN： 0002-9394            Impact factor:   5.258


× No keyword cloud information.
  5 in total

Review 1.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

2.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

Review 3.  Oral medications for central serous chorioretinopathy: a literature review.

Authors:  William Fusi-Rubiano; Habiba Saedon; Vijay Patel; Yit C Yang
Journal:  Eye (Lond)       Date:  2019-09-16       Impact factor: 3.775

Review 4.  Interventions for central serous chorioretinopathy: a network meta-analysis.

Authors:  Mahsa Salehi; Adam S Wenick; Hua Andrew Law; Jennifer R Evans; Peter Gehlbach
Journal:  Cochrane Database Syst Rev       Date:  2015-12-22

5.  Central serous chorioretinopathy: a pathogenetic model.

Authors:  Antonio Caccavale; Filippo Romanazzi; Manuela Imparato; Angelo Negri; Anna Morano; Fabio Ferentini
Journal:  Clin Ophthalmol       Date:  2011-02-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.